Research analysts at Cantor Fitzgerald decreased their FY2025 earnings per share estimates for Beam Therapeutics in a note issued to investors on Wednesday, February 26th. Cantor Fitzgerald analyst R.

Xometry (NASDAQ:XMTR – Free Report) had its target price upped by Cantor Fitzgerald from $12.00 to $20.00 in a research note issued to investors on Wednesday morning,Benzinga reports. The brokerage ...

We recently compiled a list of the 10 Best Stocks Under $50 to Buy Right Now. In this article, we are going to take a look at ...

Each Unit Includes One Class A Ordinary Share and One Share Right to Receive 1/10th of a Class A Ordinary Share ...

Blackwell is still in its early days, but at $11 billion, it made up nearly a third of Nvidia's data-center revenue, Cantor Fitzgerald analyst C.J. Muse noted. (Nvidia's data-center business ...

Fintel reports that on February 26, 2025, Cantor Fitzgerald downgraded their outlook for Jazz Pharmaceuticals (NasdaqGS:JAZZ) ...

The Central Bank said the firm failed to put effective arrangements in place to detect and report suspicious transactions.

Cantor Fitzgerald analyst Andres Sheppard reiterated a Buy rating on Intuitive Machines (LUNR – Research Report) yesterday and set a price ...

In a report released yesterday, Kristen Kluska from Cantor Fitzgerald maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), ...

In a notable holding, the Delaware Supreme Court has confirmed that forfeiture-for-competition provisions generally are not subject to ...

Spotify CEO Daniel Ek escalates battle with Apple for allegedly flouting EU's Big Tech rules, challenges EU to enforce law ...